Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The necrotic extracellular matrix (ECM) refers to the structural and biochemical environment formed following cell death and tissue devitalization, characterized by the presence of denatured and exposed collagen, glycoproteins, and proteoglycans. In healthy tissues, these components are typically sequestered or maintain a triple-helical structure; however, in necrotic conditions such as the core of solid tumors, myocardial infarctions, or chronic wounds, the loss of cellular integrity and enzymatic degradation lead to the exposure of cryptic epitopes and denatured protein chains. This unique biochemical signature makes the necrotic ECM a highly specific therapeutic target for 'necrosis-avid' agents and targeted drug delivery systems. Therapeutic strategies targeting this environment often employ collagen-binding domains (CBDs) or tumor necrosis therapy (TNT) antibodies to deliver potent payloads, such as cytokines (e.g., IL-12) or radioisotopes, directly to the site of disease. By anchoring drugs to the stable, non-diffusible scaffold of the necrotic ECM, researchers aim to enhance local retention and efficacy while reducing systemic side effects. Beyond oncology, targeting exposed collagen in the necrotic ECM is also explored in cardiovascular medicine to stabilize atherosclerotic plaques and in regenerative medicine to promote the clearance of devitalized tissue during wound healing.
Drugs targeting the necrotic extracellular matrix typically utilize high-affinity binding domains (such as collagen-binding domains or TNT antibodies) to localize therapeutic payloads (cytokines, radioisotopes, or superantigens) specifically to the necrotic core of tumors or infarcted tissue. This strategy exploits the loss of membrane integrity and the denaturation of structural proteins like collagen, which are normally sequestered from the circulation, to achieve high local concentrations of the drug while minimizing systemic toxicity.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Necrotic extracellular matrix (Necrotic ECM) (Necrotic ECM).